Panchakarma procedure and Ayurvedic medicine in the management of Yakrit Vikara w.s.r. to Alcoholic Fatty Liver Disease

A Comparative Clinical Study To Evaluate The Efficacy Of Yakrit-16 Compound- Kwatha and Tablets (Kalpit Yoga) With And Without Kalpit Kalmeghadi Niruha Basti In The Management Of Yakrit Vikara w.s.r. to Alcoholic Fatty Liver Disease - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/12/078343

Enrollment

Registered

2024-12-19

Start date

Unknown

Completion date

Unknown

Last updated

2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K700- Alcoholic fatty liver

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: a) Randomly selected irrespective of their caste, religion and sex. b) Voluntary agreement & enrolment to participate in the study. c) The ratio of AST/ALT below 2. d) Patients having alterations in Liver function tests with and without the symptoms of Kamala. e) AFLD diagnosed by abdomen ultrasonic examination of fatty liver changes grade 1 and grade 2 only. f) History of regular alcohol intake for at least 6 months.

Exclusion criteria

Exclusion criteria: a) AFLD diagnosed by abdomen ultrasonic examination of fatty liver changes grade 3 or above. b) Patients with fatty liver changes due to causes other than alcohol. c) Patients with other illness such as uncontrolled Type I and II Diabetes Mellitus, Uncontrolled Hypertension, Cerebrovascular Accident, Myocardial Infarction and Chronic Kidney Disease, HIV, Tuberculosis, Malignancies, Major Psychiatric Problems or any other serious problems. d) Patients having progressive stage of alcoholic liver disease like Hepatitis, Ascites, Cirrhosis, Cancer. e) Patients on prolonged (more than 6 weeks) medication with corticosteroids, antidepressants, anti- cholinergic, hepato-toxic medicines or any other drug that may influence the outcome of the study. f) Drug abuser. g) Pregnant and Lactating women.

Design outcomes

Primary

Measure	Time frame
Significant improvement in the clinical symptoms of AFLD: i. Aruchi (Anorexia) ii. Avipaka (Indigestion) iii. Udarshula (Abdominal Pain) iv. Agnimandya (Diminution of the Agni) v. Utklesha (Nausea) vi. Chardi (Vomiting) Timepoint: Assessment will be done in both the groups: 1. DAY 0- At the time of enrollment of the patient 1.DAY 48th-At the end of the treatment (for Group A) 2.DAY 45th-At the end of the treatment (for Group B)	—

Measure

Time frame

Significant improvement in the clinical symptoms of AFLD: i. Aruchi (Anorexia) ii. Avipaka (Indigestion) iii. Udarshula (Abdominal Pain) iv. Agnimandya (Diminution of the Agni) v. Utklesha (Nausea) vi. Chardi (Vomiting) Timepoint: Assessment will be done in both the groups: 1. DAY 0- At the time of enrollment of the patient 1.DAY 48th-At the end of the treatment (for Group A) 2.DAY 45th-At the end of the treatment (for Group B)

—

Secondary

Measure	Time frame
Significant Improvement in the objective parameters: 1.Reduction in SGOT 2.Reduction in SGPT 3.Reduction in Alkaline Phosphatase 4.Reduction in GGT Timepoint: Assessment will be done in both the groups: DAY 0- At the time of enrollment of the patient DAY 60- At the time of the follow up	—

Countries

India

Contacts

Public ContactDr Akshay Khanna

Dayanand Ayurvedic College, Jalandhar

drsanjeevsood@yahoo.com9814004142

Outcome results